With an FDA approval for HER2 ... ASCO meeting suggest that the HER2-targeting antibody-drug conjugate (ADC) can achieve meaningful clinical responses in patients with HER2- positive gastric ...
In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO ... for HER2+ metastatic gastric cancer, and recent ...
Enhertu significantly improves overall survival in HER2-positive metastatic gastric cancer compared to ramucirumab and paclitaxel. DESTINY-Gastric04 is the first phase 3 trial showing Enhertu's ...
et al. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol 16, 57 (2023). [6] Jin Li et al., HLX22 plus HLX02 and XELOX for first-line treatment of HER2-positive ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback